These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25596534)

  • 1. The concomitant management of cancer therapy and cardiac therapy.
    Salvatorelli E; Menna P; Cantalupo E; Chello M; Covino E; Wolf FI; Minotti G
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2727-37. PubMed ID: 25596534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological foundations of cardio-oncology.
    Minotti G; Salvatorelli E; Menna P
    J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
    Tajiri K; Aonuma K; Sekine I
    Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey.
    Jovenaux L; Cautela J; Resseguier N; Pibarot M; Taouqi M; Orabona M; Pinto J; Peyrol M; Barraud J; Laine M; Bonello L; Paganelli F; Barlesi F; Thuny F
    Int J Cardiol; 2017 Aug; 241():387-392. PubMed ID: 28365180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of antitumor drugs.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2008 May; 21(5):978-89. PubMed ID: 18376852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline cardiotoxicity.
    Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
    Minotti G
    J Pharmacol Exp Ther; 2013 Sep; 346(3):343-9. PubMed ID: 23818683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A historical perspective of anthracycline cardiotoxicity.
    Ewer MS; Von Hoff DD; Benjamin RS
    Heart Fail Clin; 2011 Jul; 7(3):363-72. PubMed ID: 21749888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Prevent Cardiotoxicity.
    Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
    Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of cancer chemotherapy: implications for children.
    Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE
    Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced cardiotoxicity: detection, prevention, and management.
    Truong J; Yan AT; Cramarossa G; Chan KK
    Can J Cardiol; 2014 Aug; 30(8):869-78. PubMed ID: 25064580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity and cardioprotection in childhood cancer.
    Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
    Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S84-92. PubMed ID: 27183529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.
    Wickramasinghe CD; Nguyen KL; Watson KE; Vorobiof G; Yang EH
    Future Oncol; 2016 Mar; 12(6):855-70. PubMed ID: 26829050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.
    Raschi E; Vasina V; Ursino MG; Boriani G; Martoni A; De Ponti F
    Pharmacol Ther; 2010 Feb; 125(2):196-218. PubMed ID: 19874849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing the risks of cardiac therapy in cancer patients.
    Chen CL; Parameswaran R
    Semin Oncol; 2013 Apr; 40(2):210-7. PubMed ID: 23540746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Onco-Cardiology - From the Standpoint of Cardiology].
    Shioyama W
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2052-2057. PubMed ID: 29361616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.